Breast Mass
A breast mass is any discrete lump or thickened area in the breast, whether found by a woman herself, noticed by a clinician, or identified on imaging. It is one of the most common reasons for referral to a breast clinic, and the great majority prove to be benign—cysts and fibroadenomas account for most, particularly in younger women. The difficulty is that no feature of a lump is reliable enough to distinguish benign from malignant by feel alone. A cancer can be soft and mobile; a cyst can be firm and fixed. This is why every new breast mass is assessed the same way, through a standard combination of examination, imaging, and where needed a needle biopsy, which together resolve the question with high reliability.
What is it?
The breast is composed of glandular lobules that produce milk, ducts carrying it to the nipple, fibrous supporting tissue, and fat. All of these respond to hormonal cycling, and the resulting variation in texture means that normal breast tissue is frequently lumpy, particularly in the upper outer part of the breast and in the week before a period. Distinguishing this normal nodularity from a genuine discrete mass is itself part of the assessment.
A breast mass is a discrete lesion—something that stands out from surrounding tissue as a defined lump rather than general lumpiness. The term covers a wide range of underlying causes.
The benign causes account for the overwhelming majority.
Cysts are fluid-filled sacs, most common in women in their forties and early fifties, often appearing suddenly, frequently tender, and typically varying with the menstrual cycle. They are benign and do not increase cancer risk.
Fibroadenomas are solid benign tumours composed of glandular and fibrous tissue. They are the most common mass in women in their twenties and thirties, are classically smooth, firm, rubbery, and highly mobile—often described as feeling like a marble that slips away under the fingers—and frequently remain stable for years or shrink after menopause.
Fat necrosis follows injury, surgery, or radiotherapy, where damaged fat forms a firm lump. It can feel hard and irregular and can look concerning on imaging, mimicking cancer closely enough that biopsy is sometimes needed despite a clear history of trauma.
Lipomas are soft, mobile, benign fatty lumps.
Abscesses and infection produce painful, red, warm, tender swellings, most commonly during breastfeeding but also occurring outside it, particularly in smokers, where infection beneath the nipple can become recurrent.
Galactoceles are milk-filled cysts occurring during or after breastfeeding.
Normal structures are sometimes mistaken for masses, including a prominent rib, the firm ridge of tissue along the lower border of the breast, and accessory breast tissue in the armpit which can swell and become tender cyclically.
A middle category of lesions carries uncertain potential and is managed more cautiously.
Intraductal papilloma is a small growth within a duct, often presenting with bloodstained nipple discharge rather than a palpable lump. Radial scar, despite its name, is not a scar but an area of distorted tissue that can mimic cancer on imaging. Atypical ductal or lobular hyperplasia describes abnormal cells that are not cancer but are associated with an increased future risk. Phyllodes tumour resembles a fibroadenoma but grows more rapidly and can behave aggressively, requiring wider excision. These lesions are generally excised or sampled more extensively, because a biopsy showing them may underestimate what is present in the surrounding tissue.
Malignant masses are the reason assessment exists. Invasive breast cancer typically appears as a hard, irregular mass, often fixed to surrounding tissue, though this classical description is unreliable in individual cases. Invasive lobular cancer deserves particular mention because it frequently does not form a discrete lump at all, instead producing a vague area of thickening or a change in breast texture, and it is correspondingly harder to detect by examination and on mammography.
The central point about clinical features deserves emphasis because it governs everything that follows. The classical teaching that benign lumps are smooth, mobile, and tender while malignant lumps are hard, irregular, and fixed is broadly true as a statistical tendency and unreliable in the individual case. Cancers can feel smooth and mobile, particularly some higher-grade tumours and certain subtypes. Benign lesions can feel hard and fixed, particularly fat necrosis. Pain is present in around one in six breast cancers, so the absence or presence of pain settles nothing.
This unreliability is precisely why a standardised assessment pathway exists rather than relying on clinical judgement about whether a lump feels worrying. Any new discrete breast mass warrants assessment, and the way a lump feels should influence urgency rather than whether to investigate at all.
Age shapes probability substantially. In a woman in her twenties, the great majority of masses are fibroadenomas or cysts and cancer is uncommon. In a woman in her sixties, the balance shifts considerably. This informs which imaging is used first but never removes the need for assessment, since breast cancer does occur in young women and is more likely to be aggressive when it does.
Triple assessment is the standard approach and is worth understanding, since it is what a woman will experience at a breast clinic.
Clinical examination assesses the mass and the whole breast, along with the armpit and the area above the collarbone.
Imaging follows, chosen by age. Ultrasound is used first in women under 40 and in pregnancy, where dense breast tissue limits mammography. It reliably distinguishes fluid from solid, characterises solid lesions, assesses the lymph nodes, and guides biopsy. In women over 40, mammography is performed alongside ultrasound, since it detects features such as calcifications and architectural distortion that ultrasound may not show.
Biopsy follows where imaging does not confidently establish a benign diagnosis. Core needle biopsy, using a wider needle to obtain a tissue core, is preferred over fine needle aspiration in most settings because it distinguishes invasive from non-invasive disease and provides tissue for receptor testing. It is performed under local anaesthetic, usually with ultrasound guidance, and takes a few minutes.
The findings are scored on a standardised scale from one to five at each stage—examination, imaging, and pathology—and concordance between the three is checked. Where they disagree, for instance a mass that looks benign on imaging but suspicious clinically, further assessment follows rather than accepting the reassuring result. This cross-checking is the strength of the approach.
Vacuum-assisted biopsy, which removes a larger tissue sample, is used where a standard core biopsy is insufficient or where a lesion of uncertain potential needs fuller sampling.
A finding assessed as probably benign on imaging may be managed with short-interval follow-up rather than biopsy, typically re-imaging after six months, on the basis that malignancy in this category is very uncommon and stability over time confirms the benign nature. This is a legitimate approach, though a woman who would prefer certainty can reasonably discuss biopsy instead.
Some situations modify the approach. In pregnancy and breastfeeding, ultrasound is the primary test and mammography can still be performed safely with shielding where needed; a mass during this time should be assessed rather than attributed to pregnancy changes, since pregnancy-associated breast cancer exists and is frequently diagnosed late for exactly this reason. In men, any breast lump warrants assessment, with gynaecomastia being the most common cause but male breast cancer occurring and being frequently diagnosed late. In adolescents, masses are almost always benign fibroadenomas, and biopsy is approached cautiously to avoid damaging the developing breast.
Important to Know
The reassuring statistic and the necessary action sit together here: most breast masses are benign, and every new breast mass should nonetheless be assessed. These are not in tension—assessment is what establishes the reassurance. Care is coordinated by primary care clinicians and specialist breast units.
The single most useful message is that a lump should not be watched to see whether it goes away. Normal breast tissue changes across the menstrual cycle, so a lump noticed just before a period may reasonably be reassessed after it, but a discrete mass that persists beyond one cycle warrants referral. Waiting several months to see what happens is the pattern most associated with delayed diagnosis, and it is understandable but not advisable.
Equally, how a lump feels should not determine whether it is checked. The reassuring features—soft, mobile, tender, appeared suddenly—are statistically associated with benign causes but are not reliable individually. A woman who finds a lump that feels like what she has read is harmless should still have it assessed.
Most breast clinics operate rapid-access pathways, and assessment is usually completed in one visit, with examination, imaging, and biopsy where needed all performed on the same day. Results from biopsy typically follow within a week. Understanding that the process is designed to be quick helps with the waiting, which is often the hardest part.
Treatment follows the diagnosis. Simple cysts need nothing, with aspiration available for comfort. Fibroadenomas confirmed by biopsy are usually left in place, since they are harmless and removal leaves a scar, with excision reserved for lesions that are large, growing, or causing symptoms. Fat necrosis needs no treatment once confirmed. Lipomas need nothing. Abscesses require drainage and antibiotics, and recurrent infection beneath the nipple in a smoker is unlikely to resolve without stopping smoking.
Lesions of uncertain potential are managed more actively. Papillomas, radial scars, atypical hyperplasia, and phyllodes tumours are generally excised, because the small sample from a needle biopsy may not represent the whole lesion and because some carry an increased risk of associated or future cancer. A woman told she needs an operation for a lesion that is not cancer may find this confusing, and the reason—that the biopsy may have underestimated what is there—is worth having explained.
Where cancer is diagnosed, treatment is directed by stage and by the tumour’s receptor status, and is coordinated by a multidisciplinary team. Outcomes for early-stage disease are good, and most women are treated without losing the breast.
Several specific situations deserve attention.
A mass during pregnancy or breastfeeding should be assessed rather than assumed to be related to the pregnancy. Pregnancy-associated breast cancer is uncommon but is frequently diagnosed at a later stage precisely because symptoms are attributed to normal changes. Ultrasound is safe and effective, and mammography can be performed where needed.
A breast lump in a man warrants assessment. Gynaecomastia—benign enlargement of breast tissue—is much more common, but male breast cancer occurs, typically presents as a firm lump beneath or beside the nipple, and is frequently diagnosed late because neither men nor clinicians consider it.
A lump in a woman with a known high-risk gene alteration or strong family history warrants prompt specialist assessment rather than routine referral.
A lump that has been assessed and found benign still warrants reassessment if it changes—if it grows, becomes hard, becomes fixed, or if new skin or nipple changes appear. Having had one benign lump does not protect against developing something else, and attributing a new change to a known benign diagnosis without reassessment is a recognised route to delay.
Breast awareness is more useful than rigid self-examination routines. The evidence that formal monthly self-examination reduces mortality is weak, and it has not been shown to save lives in trials. What does help is familiarity—knowing what is normal for you, so that a change is noticed and acted on. That means looking and feeling without a prescribed schedule, and reporting anything new or persistent.
Screening attendance should continue independently of any lump. A recent normal mammogram does not explain a new lump, and a lump should be assessed on its own merits regardless of when screening last occurred.
Care is coordinated by primary care with referral to specialist breast services, where triple assessment is the standard. Clinical, imaging, and pathology findings are interpreted together, with discordance between them prompting further investigation rather than acceptance of the most reassuring result.
Patient education plays an important role. Understanding that most breast masses are benign, that the way a lump feels cannot be relied upon, that assessment is usually completed quickly in a single visit, that some benign lesions are removed because biopsy may underestimate them, and that any change in a previously assessed lump warrants fresh evaluation all contribute to appropriate care.
Red flag symptoms include any new discrete lump or thickened area in the breast or armpit, in women or men; a lump that is hard, irregular, or fixed to surrounding tissue; dimpling, puckering, or tethering of the skin; redness, swelling, warmth, or an orange-peel texture, particularly if not resolving with antibiotics, which may indicate inflammatory breast cancer and requires urgent assessment; new nipple inversion or change in direction; persistent eczema-like change, scaling, or ulceration of the nipple; spontaneous discharge from a single duct, particularly if bloodstained; a change in breast size or shape; swelling above the collarbone; and any change in a lump previously assessed as benign. These warrant prompt medical evaluation.